Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Sunmax Biotechnology Co., Ltd. (4728.TWO)

Compare
388.00
+5.50
+(1.44%)
As of 10:19:32 AM GMT+8. Market Open.
Loading Chart for 4728.TWO
  • Previous Close 382.50
  • Open 389.50
  • Bid 383.50 x --
  • Ask 388.00 x --
  • Day's Range 382.00 - 389.50
  • 52 Week Range 217.00 - 408.00
  • Volume 9,468
  • Avg. Volume 46,303
  • Market Cap (intraday) 21.132B
  • Beta (5Y Monthly) 0.08
  • PE Ratio (TTM) 31.11
  • EPS (TTM) 12.47
  • Earnings Date --
  • Forward Dividend & Yield 11.00 (2.88%)
  • Ex-Dividend Date Jul 17, 2024
  • 1y Target Est --

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.

www.sunmaxbiotech.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4728.TWO

View More

Performance Overview: 4728.TWO

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4728.TWO
38.57%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
13.87%

1-Year Return

4728.TWO
75.00%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.98%

3-Year Return

4728.TWO
219.42%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
16.68%

5-Year Return

4728.TWO
644.37%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
89.91%

Compare To: 4728.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4728.TWO

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    20.83B

  • Enterprise Value

    20.56B

  • Trailing P/E

    30.70

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.98

  • Price/Book (mrq)

    13.77

  • Enterprise Value/Revenue

    21.66

  • Enterprise Value/EBITDA

    22.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    37.37%

  • Return on Assets (ttm)

    27.24%

  • Return on Equity (ttm)

    46.24%

  • Revenue (ttm)

    1.82B

  • Net Income Avi to Common (ttm)

    679.4M

  • Diluted EPS (ttm)

    12.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    865.47M

  • Total Debt/Equity (mrq)

    9.60%

  • Levered Free Cash Flow (ttm)

    400.4M

Research Analysis: 4728.TWO

View More

Company Insights: 4728.TWO

Research Reports: 4728.TWO

View More

People Also Watch